{"title":"卡马替尼治疗MET外显子14跳跃突变的转移性NSCLC成人患者的研究","authors":"T. Hida","doi":"10.1080/23808993.2021.1999585","DOIUrl":null,"url":null,"abstract":"ABSTRACT Introduction : Clinical studies of MET-targeted treatments have so far failed to provide adequate outcomes. Capmatinib, a newly designed MET receptor inhibitor, has demonstrated considerable anticancer efficacy in patients with advanced NSCLC who have a MET exon 14 skipping mutation. Areas covered : This review offers a summary of the findings from capmatinib clinical studies in NSCLC patients with a MET exon 14 skipping mutation, as well as preclinical data and post-market reporting of capmatinib. Expert opinion : Capmatinib has a tolerable safety profile and preliminary evidence of effectiveness in patients with a MET exon 14 skipping mutation, according to data from a phase 1 clinical study. The GEOMETRY mono-1 phase 2 study revealed objective response rates of 68% and 41%, and median OS of 20.8 and 13.6 months in treatment-naive and pretreated MET exon 14 skipping mutant patients, respectively. Furthermore, capmatinib penetrates the blood–brain barrier, and capmatinib activity in the brain was shown to be encouraging in the study. However, the effectiveness of immunotherapy for MET exon 14 skipping mutation remains debatable. To enhance therapy choices, researchers have begun to focus on the mechanisms of intrinsic and acquired resistance of the MET exon 14 skipping mutation.","PeriodicalId":12124,"journal":{"name":"Expert Review of Precision Medicine and Drug Development","volume":null,"pages":null},"PeriodicalIF":1.0000,"publicationDate":"2021-11-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"A profile on capmatinib in treating adult patients with metastatic NSCLC tumors with MET exon 14 skipping mutations\",\"authors\":\"T. Hida\",\"doi\":\"10.1080/23808993.2021.1999585\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"ABSTRACT Introduction : Clinical studies of MET-targeted treatments have so far failed to provide adequate outcomes. Capmatinib, a newly designed MET receptor inhibitor, has demonstrated considerable anticancer efficacy in patients with advanced NSCLC who have a MET exon 14 skipping mutation. Areas covered : This review offers a summary of the findings from capmatinib clinical studies in NSCLC patients with a MET exon 14 skipping mutation, as well as preclinical data and post-market reporting of capmatinib. Expert opinion : Capmatinib has a tolerable safety profile and preliminary evidence of effectiveness in patients with a MET exon 14 skipping mutation, according to data from a phase 1 clinical study. The GEOMETRY mono-1 phase 2 study revealed objective response rates of 68% and 41%, and median OS of 20.8 and 13.6 months in treatment-naive and pretreated MET exon 14 skipping mutant patients, respectively. Furthermore, capmatinib penetrates the blood–brain barrier, and capmatinib activity in the brain was shown to be encouraging in the study. However, the effectiveness of immunotherapy for MET exon 14 skipping mutation remains debatable. To enhance therapy choices, researchers have begun to focus on the mechanisms of intrinsic and acquired resistance of the MET exon 14 skipping mutation.\",\"PeriodicalId\":12124,\"journal\":{\"name\":\"Expert Review of Precision Medicine and Drug Development\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":1.0000,\"publicationDate\":\"2021-11-10\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Expert Review of Precision Medicine and Drug Development\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1080/23808993.2021.1999585\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"PHARMACOLOGY & PHARMACY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Expert Review of Precision Medicine and Drug Development","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1080/23808993.2021.1999585","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
A profile on capmatinib in treating adult patients with metastatic NSCLC tumors with MET exon 14 skipping mutations
ABSTRACT Introduction : Clinical studies of MET-targeted treatments have so far failed to provide adequate outcomes. Capmatinib, a newly designed MET receptor inhibitor, has demonstrated considerable anticancer efficacy in patients with advanced NSCLC who have a MET exon 14 skipping mutation. Areas covered : This review offers a summary of the findings from capmatinib clinical studies in NSCLC patients with a MET exon 14 skipping mutation, as well as preclinical data and post-market reporting of capmatinib. Expert opinion : Capmatinib has a tolerable safety profile and preliminary evidence of effectiveness in patients with a MET exon 14 skipping mutation, according to data from a phase 1 clinical study. The GEOMETRY mono-1 phase 2 study revealed objective response rates of 68% and 41%, and median OS of 20.8 and 13.6 months in treatment-naive and pretreated MET exon 14 skipping mutant patients, respectively. Furthermore, capmatinib penetrates the blood–brain barrier, and capmatinib activity in the brain was shown to be encouraging in the study. However, the effectiveness of immunotherapy for MET exon 14 skipping mutation remains debatable. To enhance therapy choices, researchers have begun to focus on the mechanisms of intrinsic and acquired resistance of the MET exon 14 skipping mutation.
期刊介绍:
Expert Review of Precision Medicine and Drug Development publishes primarily review articles covering the development and clinical application of medicine to be used in a personalized therapy setting; in addition, the journal also publishes original research and commentary-style articles. In an era where medicine is recognizing that a one-size-fits-all approach is not always appropriate, it has become necessary to identify patients responsive to treatments and treat patient populations using a tailored approach. Areas covered include: Development and application of drugs targeted to specific genotypes and populations, as well as advanced diagnostic technologies and significant biomarkers that aid in this. Clinical trials and case studies within personalized therapy and drug development. Screening, prediction and prevention of disease, prediction of adverse events, treatment monitoring, effects of metabolomics and microbiomics on treatment. Secondary population research, genome-wide association studies, disease–gene association studies, personal genome technologies. Ethical and cost–benefit issues, the impact to healthcare and business infrastructure, and regulatory issues.